![MASK 2017: ARIA digitally‐enabled, integrated, person‐centred care for rhinitis and asthma multimorbidity using real‐world‐evidence - Bousquet - 2018 - Clinical and Translational Allergy - Wiley Online Library MASK 2017: ARIA digitally‐enabled, integrated, person‐centred care for rhinitis and asthma multimorbidity using real‐world‐evidence - Bousquet - 2018 - Clinical and Translational Allergy - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/1ff7f965-80e7-4a57-ae89-8d9be3178205/clt2bf01831-fig-0001-m.jpg)
MASK 2017: ARIA digitally‐enabled, integrated, person‐centred care for rhinitis and asthma multimorbidity using real‐world‐evidence - Bousquet - 2018 - Clinical and Translational Allergy - Wiley Online Library
![PDF) Treatment response to indacaterol/glycopyrronium versus salmeterol/ fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study PDF) Treatment response to indacaterol/glycopyrronium versus salmeterol/ fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study](https://i1.rgstatic.net/publication/330236825_Treatment_response_to_indacaterolglycopyrronium_versus_salmeterolfluticasone_in_exacerbating_COPD_patients_by_gender_a_post-hoc_analysis_in_the_FLAME_study/links/5c35673792851c22a3661356/largepreview.png)
PDF) Treatment response to indacaterol/glycopyrronium versus salmeterol/ fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
![PDF) Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps PDF) Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps](https://www.researchgate.net/profile/Dermot-Ryan-2/publication/273326626/figure/fig1/AS:601695662911489@1520466833149/Spray-plume-comparison-of-MP29-02-and-marketed-intranasal-corticosteroid-formulations_Q320.jpg)
PDF) Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps
![ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem | SpringerLink ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs15007-019-1938-2/MediaObjects/15007_2019_1938_Fig3_HTML.jpg)
ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem | SpringerLink
![Novartis Virtual Asthma Theatre: Reconsidering the Potential of Inhaled Therapies in Asthma - European Medical Journal Novartis Virtual Asthma Theatre: Reconsidering the Potential of Inhaled Therapies in Asthma - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2020/11/39.jpg)
Novartis Virtual Asthma Theatre: Reconsidering the Potential of Inhaled Therapies in Asthma - European Medical Journal
![Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® ( fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® ( fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder](https://mms.businesswire.com/media/20200921005170/en/819864/4/Interactive_Media_Placeholder_webready.jpg)